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Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Although much is known
about both the cellular changes that lead to HCC and the etiological agents responsible for the majority of HCC
cases, the molecule pathogenesis of HCC is still not well understood. We aimed to determine the effect of c-Myc
gene expression on the proliferative, invasive, and migrative capabilities of hepatocellular carcinoma HepG2 cells.
Methods: A plasmid- based polymerase III promoter system was used to deliver and express short interfering RNA
targeting c-Myc to reduce its expression in HepG2 cells. Western blot analysis was used to measure the protein
level of c-Myc in HepG2 cells. The effects of c-Myc silencing on the invasion, motility, and proliferation of HepG2
cells were assessed using a Transwell chamber cell migration assay system and a growth curve assay, respectively.
Results: The data showed that plasmids expressing siRNA against c-Myc significantly decreased its expression in
HepG2 cells by up to 85%. Importantly, pSilencer-c-Myc transfected cells showed a significantly reduced potential in
migration, invasion, and proliferation.
Conclusion: C-Myc plays an important role in the development of hepatocellular carcinoma. The data show that
down-regulating the c-Myc protein level in HepG2 cells by RNAi could significantly inhibit migration, invasion and
proliferation of HepG2 cells. Thus, c-Myc might be a potential therapeutic target for hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is the most common
type of liver cancer. Most cases of HCC are secondary to
either a viral hepatitis infection (hepatitis B or C) or
cirrhosis (alcoholism being the most common cause of
hepatic cirrhosis) [1]. Although much is known about
both the cellular changes that lead to HCC and the
etiological agents responsible for the majority of HCC
cases (hepatitis B virus, hepatitis C virus, alcohol), the
molecule pathogenesis of HCC is still not well under-
stood [2,3].* Correspondence: zhangh468@sohu.com; wcj902@163.com
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reproduction in any medium, provided the orMyc (c-Myc) is a regulator gene that encodes for a
transcription factor. A mutated version of Myc is found
in many cancers, which causes Myc to be constitutively
(persistently) expressed. This further induces an unregu-
lated expression of several genes, some of which are
involved in cell proliferation [4]. A frequent genetic
abnormality seen in HCC is the overexpression of c-Myc
[5,6]. The importance of c-Myc expression in HCC is
demonstrated both by studies of transgenic mice [7,8] and
clinical research which has indicated that overexpression
of c-Myc is found in most HCC patients and correlated
with poor prognosis [9].
A recent study demonstrates that temporary inhibition
of Myc selectively kills mouse lung cancer cells or induces
apoptosis, making it a potential cancer drug target [10,11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and is believed to regulate expression of 15% of all
genes [12] through binding on Enhancer Box sequen-
ces (E-boxes) and recruiting histone acetyltransferases
(HATs). This means that in addition to its role as a clas-
sical transcription factor, Myc also functions to regulate
global chromatin structure by regulating histone acety-
lation both in gene-rich regions and at sites far from any
known genes [13]. In this study, we aimed to investigate
whether specific down-regulating the protein level of
c-Myc in a HepG2 cell line might result in the inhibition
of cell growth.
RNA interference (RNAi) is a process in which
activation of an intracellular pathway modulated by
small-interfering RNA (siRNA) composed of 21–23 nu-
cleotides (nt) leads to degradation of a specific, targeted
mRNA [14]. The selective and robust effect of RNAi on
gene expression makes it a valuable research tool, both
in cell culture and in living organisms because synthetic
dsRNA introduced into cells can induce suppression of
specific genes of interest [15,16]. RNAi has been used to
inhibit diseases induced by virus (for instance, HIV [17]
and influenza [18]), tumorigenesis caused by oncogenic
K-ras, and H-ras [19,20], activation of oncogenes resulting
from chromosomal translocations (for example bcr/abl in
chromic myeloid leukemia [21]), cancers caused by viral in-
fections, and others. Recently, retroviral-based approaches
to deliver siRNA into tissue cultured mammalian cells have
been proved to be powerful, and doxycycline-regulated in-
ducible gene expression by RNAi has been shown to be
particularly useful for the analysis of genes that are neces-
sary for cellular survival (22,23). These studies have
established a new area in the genetic manipulation of hu-
man cancer development by allowing oncogenes to be
down regulated by RNAi. For this purpose, RNAi directed
against c-Myc was used here.
In this study, HepG2 cell was transfected with a plas-
mid which was under the control of the U6 promoter to
deliver and express siRNA targeting c-Myc to determine
whether this technique could be used for the specific in-
hibition of oncogene overexpression and whether this
inhibition resulted in antitumor effects. Our results
showed that specific down-regulation of c-Myc by RNAi
was sufficient to inhibit the proliferative, invasive, and
migrative capabilities of HepG2 cell, and that c-Myc
might serve as a therapeutic target for HCC.
Results
Selection of siRNA transfectants
HepG2 cells were co-transfected with pSILENCER 1.0-U6
generating short hairpin siRNA and with pEF6/V5-His
TOPO expression vector carrying selectable blasticidin
marker as described in the Materials and Methods section.
Transfected cells were selected for blasticidin resistanceand characterized by the presence of the insert in the ge-
nomic DNA (data not shown).
Suppression of c-Myc expression in HepG2 cells by RNAi
One pair of oligonucleotides encoding short hairpin
trans cripts directed against a portion of the c-Myc
mRNA was designed and synthesized. This pair of oligo-
nucleotide was then ligated into pSilencer. The plasmid
of pSilencer–c-Myc contains a U6 promoter that directs
the synthesis of oligonucleotides in an inverted repeat
with 9 nt for its loop, with six T bases added at the end
to serve as a termination signal for RNA polymerase III.
The RNA is expected to fold back to form a hairpin loop
structure after being transcribed; the hairpin dsRNA can
then be further cleaved by Dicer to generate a 21-
nucleotide siRNA, the active form for the RNAi effect,
which will form dsRNA–endonuclease complexes and
will bind and destroy c-myc mRNA inside cells [17]
(Figure 1).
PSilencer–c-Myc was transfected into HepG2 cells and
its effects on c-Myc protein levels were determined by
comparison with pSilencer-transfected cells by western
blot at the time points indicated. We found that the
c-Myc expression levels were suppressed by up to 85%
in HepG2 cells at day 4 after transfection. Actually the
levels of c-Myc were decreased as early as 24 hours after
transfection and remained at low levels until 8 days after
transfection (Figure 2). Our obtained inhibition rate by
siRNA seemed to be higher than that in previous report
(67%), which demonstrated better cell transfection effi-
ciency in our study [11]. The inhibitory effect was shown
to be specific because transfection with pSilencer did
not alter c-Myc levels. In addition, RNAi did not cause a
nonspecific down-regulation of gene expression, as de-
termined by the β-actin control (Figure 2). These data
indicated that vector-based RNAi could effectively sup-
press c-Myc overexpression and resulted in prolonged
decreases in specific cellular gene expression without
marked effects on other cellular proteins.
Effect of siRNA c-Myc on cell invasion, motility, and
proliferation
The in vitro invasion assay was designed to test
whether transfection of siRNA c-Myc altered the in-
vasive potential of tumor cells in Matrigel-coated
transwell chamber. Considering as 100% in the un-
treated HepG2 cells which are able to invade to the
filters in 24 hours, the invasive percentage of vector
alone–transfected cells was 83% and that of siRNA c-
Myc–transfected cells was 27% (Figure 3a). The inva-
sive potential of pS siRNA c-Myc cells significantly
decreased (P < 0.05).
To study the effect of siRNA c-Myc transfection on
migration, parental and transfected cells were seeded
Figure 1 Schematic drawing of the pSliencer 1.0-U6 vector. The U6-RNA promoter was cloned in front of the gene-specific targeting
sequence (19-nucleotide sequences from the target transcript separated by a short spacer from the reverse complement of the same sequence)
and six thymidines (T6) as a termination signal.
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24 hours of incubation, the motility potential of
pS siRNA c-Myc cells was significantly reduced
(Figure 3b; P < 0.05).
To determine changes in the growth pattern of
HepG2 cells stably transfected with siRNA c-Myc, a
growth curve was done on them along with parental
cells and the cells transfected with the empty vector.
c-Myc inhibition by siRNA c-Myc transfection
modulated the proliferation of hepatocellular carcin-
oma cells; in fact, the proliferation of pS siRNA c-
Myc cells was markedly decreased compared with
parental and vector-alone–transfected cells (P < 0.05)
(Figure 3c), indicating that c-Myc is involved in the
proliferative potential of hepatocarcinoma cells.
In summary, inhibition of endogenous c-Myc using
siRNA technology could reduce the motility, invasion,
and proliferation of HCC cells. Although we obtained
comparable c-Myc inhibition with plasmid expressing
antisense c-Myc mRNA, the advantages provided by
siRNA technology should be relevant for in vivo stu-
dies avoiding nonspecific defense responses against
duplex RNA longer than 30 nt [18-20]. In addition,
future studies should be performed to test the effect
of c-Myc silencing on the other HCC cells.Figure 2 Time course of the reduction in c-Myc protein levels by pSil
transfected with pS–c-Myc or pSilencer (pS) and whole cell lysates were pre
SDS–PAGE and immune blotted with an antibody against c-Myc; expressioConclusions
Our findings confirm that down-regulation of c-Myc may
be an effective way of achieving a significant reduction in
the malignant properties of HCC-derived cells and imply
the therapeutic potential of RNAi on the treatment of
hepatocellular carcinoma by targeting overexpression on-
cogenes such as c-Myc.
Materials and methods
Reagents
RPMI 1640 medium (Life Technologies, Inc., Gaithersburg,
MD); pEF6/V5-HisvTOPO vector (Invitrogen; the plasmid
containing the blasticidin-selectable marker gene); DOTAP
Liposomal transfection reagent according to the manufac-
turer’s instructions (Invitrogen); anti-c-Myc (9E10; 1:1000
dilution; Santa Cruz) and anti-β-actin (AC-15; 1:5000
dilution; Sigma), anti-mouse IgG–horseradish peroxidase
conjugate antibody (Zhongshan Company); Luminol
chemiluminescence detection kit (Santa Cruz).
Cell line and cell culture
The HepG2 human cell line was provided by the Shanghai
Cell Research Institution of Chinese Academy of Sciences.
The cells were cultured with RPMI 1640 medium
supplemented with 100 mL/L fetal calf serum, 1*105 U/Lencer-c-Myc (pS-c-Myc). Exponentially proliferating HepG2 cells were
pared at the time points indicated. Total cell lysates were separated by
n levels were normalized for loading by probing for β-actin.
Figure 3 Invasion (a), motility (b) and proliferation (c) of parental, vector, and siRNAi-vector transfected cells. The percentages of
invading (t=24 hours) and migrating (t=24 hours) cells were calculated as reported in Materials and Methods. The pictures highlighted the
differences in number between HepG2, pS, and pS-c-Myc cells able to invade (a) or migrate (b) to the lower surface of transwells. RNAi directed
against c-Myc led to a reduced cellular growth rate after 24, 48 and 72 hours. Columns, averages of three independent experiments; error bars,
SD. *P <0.05.
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incubator.
Design and preparation of constructs
To design siRNA targeting c-Myc, one annealed set of
oligonucleotides (for 3 minutes at 90°C and for 1 hour
at 37°C) encoding short hairpin transcripts correspond-
ing to 1906–1926 nt of c-Myc mRNA (GenBank acces-
sion no. NM-002467) [21] were cloned into pSilencer
1.0-U6 (containing ampicillin resistance gene and the
human U6 RNA Polymerase III promoter). The short-
hairpin-RNA-encoding complementary single-stranded
oligonucleotides, which hybridized to give overhangs
compatible with ApaI and EcoRI, were designed with a
computer program available on the Internet (http://
www.ambion.com/techlib/misc/psilencerconverter.html.)
Oligonucleotides encoding short hairpin RNAs were
then ligated into pSilencer. Bacterial colonies were
pooled and used for plasmid preparation. The positive
clones were confirmed by sequencing. The resulting
plasmid was designated as pSilencer–c-Myc. The se-
quence of the insert was confirmed by automated se-
quencing and analyzing the fragments generated from
digestion with HindIII.
Transfection of cells
HepG2 cells were grown to 60% to 80% confluency
(in 6- cm-diameter Petri dishes) and then co-transfected
with 10 ug of pSILENCER 1.0-U6 and 1 ug of pEF6/V5-
HisvTOPO vector using DOTAP Liposomal transfection
reagent. Transfected cells were selected for blasticidin
resistance (6 ug/mL; pS: cells transfected with vector-
alone; pS siRNA C-Myc: cells transfected with siRNA
against C-Myc).
Western blot analysis
The 24-hour serum-free conditioned media (2 mL/6-cm
diameter Petri dish) were collected from confluent cul-
tures of parental, pS, and pS siRNA c-Myc transfected
cells. Constant amounts of proteins from conditioned
media of transfected and non-transfected cells were
loaded in SDS-PAGE, under non-reducing conditions, on
a polyacrylamide gel composed of three layers, containing
different acrylamide concentrations. Gel was blotted on
nitrocellulose membranes and immune reacted with anti-
bodies. The antibodies and dilutions used were anti-
c-Myc (9E10; 1:1000 dilution; Santa Cruz) and anti-β-actin
(AC-15; 1:5000 dilution; Sigma). After being washed
extensively, the membranes were incubated with anti-
mouse IgG–horseradish peroxidase conjugate antibody
(Zhongshan Company) for 1 hour at room temperature
and developed with Luminol chemiluminescence detec-
tion kit (Santa Cruz). Membranes probed for β-actin was
used to normalize for loading and/or quantification errorsand to allow comparisons of target protein expression.
Protein expression was quantified with a Gel EDAS analysis
system (Cold Spring USA Corporation) and Gel-Pro
Analyzer 3.1 software (Media Cybernetics).
Invasion and motility
Invasion assay was done in a 24-well transwell chamber.
Cells were added to coated filters in 100 μL of serum-
free medium in triplicate wells. In the lower compart-
ments of the chambers, 600 μL of human fibroblast-
serum-free-conditioned media was used as chemo
attractant. After 24 hours at 37°C in a 5% CO2 incubator,
the Matrigel coating on the upper surface of the filter
was wiped off using a cotton swab. Cells that migrated
through the filters were fixed, stained with Hema-3,
photographed, and counted. The motility assay was
conducted in a similar procedure. Cells were loaded on
transwell polycarbonate membrane inserts in triplicate
wells. The plates were incubated for 24 hours at 37°C in
a 5% CO2 incubator, the cells in the lower wells were
fixed, stained with Hema-3, and counted. The cells that
had migrated to the lower compartment of the chambers
were trypsinized and counted. Each experiment was car-
ried out in triplicate. The statistical significance of the
results was calculated using the ANOVA procedure. The
data were considered to be significant when P < 0.05.
Proliferation assay
HepG2 and HepG2-transfected cells were seeded in tripli-
cate in 3-cm-diameter Petri dishes. After 24, 48, and
72 hours of incubation at 37°C, the cells were trypsinized
and counted using a Burker chamber.
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